Structural basis of respiratory syncytial virus neutralization by motavizumab.

Nature Structural & Molecular Biology
Jason S McLellanPeter D Kwong

Abstract

Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.

References

Jul 1, 1994·Biopolymers·R NorelR Nussinov
Dec 20, 1993·Journal of Molecular Biology·M C Lawrence, P M Colman
May 30, 2002·Protein Engineering·Brian J SmithPeter M Colman
Jan 9, 2003·JAMA : the Journal of the American Medical Association·William W ThompsonKeiji Fukuda
Nov 6, 2004·The Journal of Infectious Diseases·Xiaodong ZhaoWayne M Sullender
Aug 8, 2007·Journal of Molecular Biology·Evgeny Krissinel, Kim Henrick
Feb 12, 2008·Nature Structural & Molecular Biology·Shee-Mei LokMichael G Rossmann
Aug 1, 2008·Nature·Jun LiuSriram Subramaniam

❮ Previous
Next ❯

Citations

May 30, 2012·Nanoscale·Kellen M HarknessDavid E Cliffel
May 19, 2011·Proceedings of the National Academy of Sciences of the United States of America·Kurt A SwansonAndrea Carfi
Feb 11, 2012·Proceedings of the National Academy of Sciences of the United States of America·Margarita MagroConcepción Palomo
Oct 15, 2011·The Journal of Infectious Diseases·Barney S Graham
Feb 7, 2014·Nature·Bruno E CorreiaWilliam R Schief
Oct 13, 2011·Expert Review of Vaccines·Julia L Hurwitz
Jun 13, 2015·International Journal of Molecular Sciences·Enrico MalitoMatthew J Bottomley
Jan 26, 2013·Journal of Peptide Science : an Official Publication of the European Peptide Society·John A Robinson
Oct 16, 2015·Science Translational Medicine·Joan O NgwutaBarney S Graham
Nov 4, 2015·Journal of Immunology Research·Lassi LiljeroosMatthew James Bottomley
Mar 30, 2016·The Journal of Experimental Medicine·Rino RappuoliEnnio De Gregorio
Sep 4, 2015·Nature Communications·Anders KrarupJohannes P M Langedijk
Jun 13, 2015·Current Opinion in Immunology·Barney S GrahamJason S McLellan
Mar 31, 2015·Current Opinion in Virology·Jason S McLellan
Mar 10, 2015·The Journal of Clinical Investigation·Jeanne H SchickliDavid R Milich
Aug 2, 2016·Nature Structural & Molecular Biology·M Gordon JoycePeter D Kwong
Aug 25, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Pierre-Louis HervéSabine Riffault
Apr 12, 2016·Molecular BioSystems·Jillian N WhelanMichael N Teng
Oct 9, 2014·Nature·Marie PanceraPeter D Kwong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.